Document is current
Any future updates will be listed below
-
Authors
Nakajima, Hanako
Nakanishi, Naoko http://orcid.org/0000-0003-0092-2593
Miyoshi, Tomoki
Okamura, Takuro
Hashimoto, Yoshitaka
Senmaru, Takafumi
Majima, Saori
Ushigome, Emi
Asano, Mai
Yamaguchi, Mihoko
Mori, Jun
Sakui, Norihiro
Sasano, Ryoichi
Yamazaki, Masahiro
Hamaguchi, Masahide
Fukui, Michiaki
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JSPS KAKENHI Grant Number 19K23999)
- License Information
-
More Information
Article History
Received: 1 October 2021
Accepted: 12 July 2022
First Online: 28 July 2022
Declarations
:
: The protocols of this study were approved by the Committee for Animal Research, Kyoto Prefectural University of Medicine.
: All authors consent to the publication of the manuscript.
: N.N received grant support from Japan Society for the Promotion of Science (JSPS KAKENHI Grant Number 19K23999) (JSPS KAKENHI Grant Number 20K16158) and The Japan Food Chemical Research Foundation, and received personal fees from Novo Nordisk Pharma Ltd. and Kowa Pharmaceutical Co. Ltd. Y.H. received grants from Asahi Kasei Pharma, and received personal fees from Novo Nordisk Pharma Ltd., Sanofi K.K., Ono Pharmaceutical Co., Ltd., Kowa Co. Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Daiichi Sankyo Co. Ltd., and Mitsubishi Tanabe Pharma Co., outside the submitted work. T.S. received personal fees from Kowa Pharma Co. Ltd., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Co, Novo Nordisk Pharma Ltd., Takeda Pharma Co., Ltd., Sanofi K.K., Kissei Pharma Co., Ltd., Taisho Toyama Pharma Co. Ltd., Astellas Pharma Inc., Kyowa Hakko Kirin Co. Ltd.,MSD K.K. and Ono Pharma Co. Ltd. outside the submitted work. E.U. received grant support from the Japanese Study Group for Physiology and Management of Blood Pressure, the Astellas Foundation for Research on Metabolic Disorders (Grant number: 4024), the Japan Society for the Promotion of Science, Mishima Kaiun Memorial Foundation,and received personal fees from Daiichi Sankyo Co. Ltd, Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical Company Ltd., MSD K.K., Ono Pharmaceutical Co. Ltd., Kowa Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Co., Taisho Pharmaceutical Co. Ltd., Sanofi K.K., and AstraZeneca K.K., outside the submitted work. Donated Fund Laboratory of Diabetes therapeutics is an endowment department, supported with an unrestricted grant from Taisho Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., and Taiyo Kagaku Co. Ltd. M.A. received personal fees from Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Kowa Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Abbott Japan Co. Ltd., AstraZeneca K.K., and Ono Pharmaceutical Co. Ltd., outside the submitted work. M.Y. received personal fees from Sumitomo Dainippon Pharma Co. Ltd., MSD K.K., Daiichi Sankyo Co. Ltd., Kowa Co. Ltd., AstraZeneca PLC., Ono Pharmaceutical Co, Ltd., Kyowa Hakko Kirin Co. Ltd., Kowa Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd. outside the submitted work. M.H. received grants from Ono Pharma Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., AstraZeneca K.K., Yamada Bee Farm, Oishi Kenko inc., and received personal fees from Ono Pharma Co. Ltd., AstraZeneca K.K., Sumitomo Dainippon Pharma Co, Ltd., Kowa Pharma Co. Ltd.,Mitsubishi Tanabe Pharma Corp., Daiichi Sankyo Co. Ltd., Sanofi K.K., and Eli Lilly, Japan, outside the submitted work. M.F. received grants from Takeda Pharma Co. Ltd.,Ono Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corp., Oishi Kenko inc., Taisho Pharma Co. Ltd.,MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Kissei Pharma Co. Ltd., Daiichi Sankyo Co. Ltd., Sanofi K.K., Novo Nordisk Pharma Ltd.,Astellas Pharma Inc., Tejin Pharma Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kowa Pharma Co. Ltd., Sanwa Kagagu Kenkyusho CO. Ltd., Eli Lilly, Japan, K.K., Terumo Corp., Kyowa Kirin Co. Ltd.,Yamada Bee Farm, Nippon Chemiphar Co., Ltd., Abbott Japan Co. Ltd., and Johnson & Johnson K.K. Medical Co., and received personal fees from Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corp., Kowa Pharma Co. Ltd., Sanofi K.K., Taisho Pharma Co., Ltd., Takeda Pharma Co. Ltd., Astellas Pharma Inc., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kissei Pharma Co., Ltd., Novo Nordisk Pharma Ltd., MSD K.K., Ono Pharma Co. Ltd., Sanwa Kagaku Kenkyusho Co. Ltd., Eli Lilly Japan K.K., Bayer Yakuhin, Ltd., Abbott Japan Co. Ltd., AstraZeneca K.K., Daiichi Sankyo Co. Ltd., Mochida Pharma Co. Ltd., Teijin Pharma Ltd., Terumo Corp, Medtronic Japan Co. Ltd., Nipro Corp. and Arkray Inc., outside the submitted work. The other authors have nothing to disclose. The authors declare that there are no competing of interest.
